Subscribe Sign In

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/ozempic-mounjaro-weight-loss-drug-wegovy-eli-lilly-66f2906

The ‘King Kong’ of Weight-Loss Drugs Is Coming

Eli Lilly’s Mounjaro could outpace Ozempic as the most powerful treatment on the market. To develop it, the drug company needed to overhaul long-held but failing practices.

Todd Suter, senior principal biologist, at a lab at Eli Lilly headquarters in Indianapolis.

Todd Suter, senior principal biologist, at a lab at Eli Lilly headquarters in Indianapolis.

By Peter Loftus

| Photographs by Maddie McGarvey for The Wall Street Journal

April 3, 2023 10:31 am ET

People who are overweight are flocking to the drug Ozempic to slim down. Looming is an even more powerful weight-loss treatment.

The drug Mounjaro helped a typical person with obesity who weighed 230 pounds lose up to 50 pounds during a test period of nearly 17 months.

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Already a subscriber? Sign In